

**INFORMATION ABOUT THE FACTS AND CIRCUMSTANCES OCCURRED  
DURING THE FIRST QUARTER OF 2024  
OF SOPHARMA GROUP**

**Annex № 4**

**To Art. 12, par. 1, it.1, art.14 of Ordinance № 2 from 09.11.2021  
And Regulation (EU) 596/2014 of the European Parliament and of the Council  
of 16 April 2014**

*The persons who are liable for damages caused by false, misleading or incomplete data in this information as of 31.03.2024 are:*

*Ognyan Donev - Executive Director and Chairman of the Board of Directors of Sopharma AD  
Vesela Stoeva – Deputy. - Chairman of the Board of Directors of Sopharma AD  
Bisera Lazarova – Member of the Board of Directors of Sopharma AD  
Alexander Chaushev – Member of the Board of Directors of Sopharma AD  
Ivan Badinski - Member of the Board of Directors of Sopharma AD*

- 1.1. No change in the persons controlling the Company.
- 1.2. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.
- 1.3. No conclusion or execution of significant transactions.
- 1.4. No decision on conclusion, termination and cancellation of joint venture agreements.
- 1.5. Change of the auditors of the company - No change of auditors.
- 1.6. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.
- 1.7. No purchases, sales or established pledges of shares in commercial companies by the issuer or its subsidiary.
- 1.8. The management believes that the military conflict between Russia and Ukraine could have a serious impact on the Company's activities, since the main part of product sales are realized in Ukraine and Russia.

The company has investments in two subsidiaries in Ukraine. As of the date of preparation of the financial statements, the assets of these subsidiaries are not physically affected by military action, but it is possible that in the future the value of these investments may need to be reviewed depending on the development of the war and its impact on the activities of the companies.

“Sopharma” AD informs all interested parties that the consolidated financial statements of the Company as at 31 March 2024 have not been verified by a registered auditor.